Eli Lilly posts 48% revenue growth driven by blockbuster obesity drugs

Name: Eli Lilly posts 48% revenue growth driven by blockbuster obesity drugs
Uploaded: 2026-08-05T17:27:50Z
Duration: 2 min 38 s
Description: Taylor Riggs, Lou Bassanese, and David Bahnsen discuss Eli Lilly's blowout earnings, driven by its blockbuster obesity and diabetes drugs Mounjaro and Zepbound, and weigh in on the company's long-term reliance on these products.

The Big Money Show · FBN · Aired Today · 2m 38s

Watch Now

Already a subscriber?

Taylor Riggs, Lou Bassanese, and David Bahnsen discuss Eli Lilly's blowout earnings, driven by its blockbuster obesity and diabetes drugs Mounjaro and Zepbound, and weigh in on the company's long-term reliance on these products.